论文部分内容阅读
目的探讨甘精胰岛素对T2DM患者血浆游离胰岛素样生长因子-1(FIGF-1)、胰岛素样生长因子结合蛋白-1(IGFBP-1)、血管内皮细胞生长因子(VEGF)的影响。方法将患者随机分为甘精胰岛素治疗组和中性胰岛素(NPH)治疗组,比较两组在治疗0,3,6,12个月时血浆HbA1c、FIGF-1、IGFBP-1、VEGF浓度及治疗期间发生低血糖次数。结果甘精胰岛素治疗组HbA1c、VEGF在治疗后6、12个月与NPH治疗组差异均有统计学意义(P均<0.05);IGFBP-1在治疗后3、6、12个月明显低于NPH治疗组(P<0.05);两组FIGF-1差异均无统计学意义(P>0.05);两组低血糖发生次数差异有统计学意义(P<0.05)。结论与NPH比较,甘精胰岛素能更好地控制血糖,增加患者血浆VEGF,降低IGFBP-1,对FIGF-1无影响。
Objective To investigate the effects of insulin glargine on plasma free insulin-like growth factor-1 (FIGF-1), insulin-like growth factor binding protein-1 (IGFBP-1) and vascular endothelial growth factor (VEGF) in T2DM patients. Methods The patients were randomly divided into insulin glargine group and NPH group. The plasma levels of HbA1c, FIGF-1, IGFBP-1 and VEGF were compared between the two groups at 0, 3, 6 and 12 months Hypoglycemia occurred during treatment. Results The levels of HbA1c and VEGF in glargine group were significantly different from those in NPH group at 6 and 12 months after treatment (all P <0.05). IGFBP-1 was significantly lower at 3, 6 and 12 months after treatment NPH treatment group (P <0.05). There was no significant difference in FIGF-1 between the two groups (P> 0.05). There was significant difference in the number of hypoglycemia between the two groups (P <0.05). Conclusion Compared with NPH, insulin glargine can better control blood glucose, increase plasma VEGF, reduce IGFBP-1, FIGF-1 has no effect.